The molecular diagnosis of triple-negative breast cancer is primarily based on the IHC of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [27]. Here, PGR is linked to triple-negative breast carcinoma.